» Articles » PMID: 34976720

Bladder Myeloid Sarcoma with Mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndrome: Response to Decitabine-Venetoclax Regimen

Overview
Journal Leuk Res Rep
Date 2022 Jan 3
PMID 34976720
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Myeloid sarcoma (MS) is a rare extramedullary blast proliferation of immature cells of myeloid origin. It is commonly associated with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or myeloproliferative neoplasm (MPN), and may precede, coincide with, or follow the diagnosis of a myeloid disorder. MS treatment is controversial, but AML induction like regimens is usually recommended. We present an unusual case of mutated MDS/MPN overlap with bladder MS. Due to the high-risk nature of the disease, the patient was induced with decitabine and venetoclax combination therapy, resulting in complete remission. The response was further consolidated by an allogeneic hematopoietic stem cell transplantation.

Citing Articles

Macroscopic Hematuria Revealing Bladder Myeloid Sarcoma in Acute Myeloid Leukemia.

Halloumi O, Sebastian W, Harb M, Trepant A, Andreozzi F Cureus. 2025; 16(12):e75912.

PMID: 39830569 PMC: 11739638. DOI: 10.7759/cureus.75912.


Myeloid Sarcoma: Novel Advances Regarding Molecular Pathogenesis, Presentation and Therapeutic Options.

Diamantidis M J Clin Med. 2024; 13(20).

PMID: 39458104 PMC: 11509401. DOI: 10.3390/jcm13206154.


Myeloid sarcoma with plasmacytoid dendritic cell-like proliferation associated with IKZF1, ETV6 and DNMT3A mutations.

Suzuki K, Koyama D, Oka Y, Sato Y, Sekine R, Fukatsu M Int J Hematol. 2024; 120(3):382-388.

PMID: 38861243 DOI: 10.1007/s12185-024-03806-z.


Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma.

Jian X, Cha J, Lin Z, Xie S, Huang Y, Lin Y Discov Oncol. 2024; 15(1):210.

PMID: 38834922 PMC: 11150210. DOI: 10.1007/s12672-024-01068-z.


Lymph node myeloid sarcoma with TP53‑associated myelodysplastic syndrome: A case report.

Mao M, Deng S Oncol Lett. 2024; 28(1):324.

PMID: 38807682 PMC: 11130743. DOI: 10.3892/ol.2024.14458.


References
1.
Kaur V, Swami A, Alapat D, Abdallah A, Motwani P, Hutchins L . Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years. Hematology. 2017; 23(1):17-24. DOI: 10.1080/10245332.2017.1333275. View

2.
Almond L, Charalampakis M, Ford S, Gourevitch D, Desai A . Myeloid Sarcoma: Presentation, Diagnosis, and Treatment. Clin Lymphoma Myeloma Leuk. 2017; 17(5):263-267. DOI: 10.1016/j.clml.2017.02.027. View

3.
Bakst R, Tallman M, Douer D, Yahalom J . How I treat extramedullary acute myeloid leukemia. Blood. 2011; 118(14):3785-93. DOI: 10.1182/blood-2011-04-347229. View

4.
Chin T, Masir N, Noor Hussin H, Sidik S, Boon Cheok L, Yean T . Myeloid sarcoma of the urinary bladder with cutaneous tumour seeding after percutaneous suprapubic catheterization. Malays J Pathol. 2011; 33(1):47-51. View

5.
Byrd J, Edenfield W, Dow N, Aylesworth C, Dawson N . Extramedullary myeloid cell tumors in myelodysplastic-syndromes: not a true indication of impending acute myeloid leukemia. Leuk Lymphoma. 1996; 21(1-2):153-9. DOI: 10.3109/10428199609067593. View